Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 16-006798
    NCT ID: NCT03019029
    Sponsor Protocol Number: 16-006798

About this study

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Adults: 18-100
  • Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy

Exclusion Criteria:

  • Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
  • Kidney Disease/Poor Renal Function
  • Elevated creatinine levels
  • Seizures
  • Asthma
  • Hemolytic anemia
  • Claustrophobia
  • BMI over 45

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Broski, M.D.

Open for enrollment

Contact information:

Terry Brinkman CCRP


More information

Study Progress

This study has completed enrollment of targeted participants and currently is completing research activities including study intervention, specimen collection, testing and data analysis.


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available